CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2 KEY BENEFITS

1.1.1. Secondary research
1.1.2. Primary research
1.1.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. PORTERS FIVE FORCES ANALYSIS
3.4. CLINICAL TRIALS
3.5. MARKET SHARE ANALYSIS, 2016
3.6. MARKET DYNAMICS

3.6.1. Drivers

3.6.1.1. Growing prevalence of ulcerative colitis disease
3.6.1.2. Increase in R&D and investment by key players towards development of novel drug therapies
3.6.1.3. Rise in government and non-government organization focus towards research in biologics

3.6.2. Restraints

3.6.2.1. Patent expiry of drugs
3.6.2.2. Stringent government regulations towards approval of biosimilars

3.6.3. Opportunities

3.6.3.1. Untapped emerging economies

CHAPTER 4 ULCERATIVE COLITIS, BY DISEASE TYPE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. MILD ULCERATIVE COLITIS

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. MODERATE ULCERATIVE COLITIS

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. SEVERE ULCERATIVE COLITIS

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

CHAPTER 5 ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. SMALL MOLECULES

5.2.1. Market size and forecast

5.3. BIOLOGICS

5.3.1. Market size and forecast

CHAPTER 6 ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. ORAL

6.2.1. Market size and forecast

6.3. INJECTABLES

6.3.1. Market size and forecast

CHAPTER 7 ULCERATIVE COLITIS MARKET, BY GEOGRAPHY

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. NORTH AMERICA

7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. North America Market Size and Forecast for Ulcerative Colitis Market by Country
7.2.4. North America Market Size and Forecast for Ulcerative Colitis Market by Disease Type
7.2.5. North America Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
7.2.6. North America Market Size and Forecast for Ulcerative Colitis Market by Route of Administration

7.2.6.1. U.S. Market Size and Forecast for Ulcerative Colitis Market by Disease Type
7.2.6.2. U.S. Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
7.2.6.3. U.S. Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
7.2.6.4. Canada Market Size and Forecast for Ulcerative Colitis Market by Disease Type
7.2.6.5. Canada Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
7.2.6.6. Canada Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
7.2.6.7. Mexico Market Size and Forecast for Ulcerative Colitis Market by Disease Type
7.2.6.8. Mexico Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
7.2.6.9. Mexico Market Size and Forecast for Ulcerative Colitis Market by Route of Administration

7.3. EUROPE

7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Europe Market Size and Forecast for Ulcerative Colitis Market by Country
7.3.4. Europe Market Size and Forecast for Ulcerative Colitis Market by Disease Type
7.3.5. Europe Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
7.3.6. Europe Market Size and Forecast for Ulcerative Colitis Market by Route of Administration

7.3.6.1. Germany Market Size and Forecast for Ulcerative Colitis Market by Disease Type
7.3.6.2. Germany Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
7.3.6.3. Germany Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
7.3.6.4. UK Market Size and Forecast for Ulcerative Colitis Market by Disease Type
7.3.6.5. UK Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
7.3.6.6. UK Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
7.3.6.7. Italy Market Size and Forecast for Ulcerative Colitis Market by Disease Type
7.3.6.8. Italy Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
7.3.6.9. Italy Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
7.3.6.10. France Market Size and Forecast for Ulcerative Colitis Market by Disease Type
7.3.6.11. France Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
7.3.6.12. France Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
7.3.6.13. Spain Market Size and Forecast for Ulcerative Colitis Market by Disease Type
7.3.6.14. Spain Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
7.3.6.15. Spain Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
7.3.6.16. Rest of Europe Market Size and Forecast for Ulcerative Colitis Market by Disease Type
7.3.6.17. Rest of Europe Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
7.3.6.18. Rest of Europe Market Size and Forecast for Ulcerative Colitis Market by Route of Administration

7.4. ASIA-PACIFIC

7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Asia-Pacific Market Size and Forecast for Ulcerative Colitis Market by Country
7.4.4. Asia-Pacific Market Size and Forecast for Ulcerative Colitis Market by Disease Type
7.4.5. Asia-Pacific Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
7.4.6. Asia-Pacific Market Size and Forecast for Ulcerative Colitis Market by Route of Administration

7.4.6.1. Japan Market Size and Forecast for Ulcerative Colitis Market by Disease Type
7.4.6.2. Japan Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
7.4.6.3. Japan Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
7.4.6.4. China Market Size and Forecast for Ulcerative Colitis Market by Disease Type
7.4.6.5. China Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
7.4.6.6. China Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
7.4.6.7. India Market Size and Forecast for Ulcerative Colitis Market by Disease Type
7.4.6.8. India Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
7.4.6.9. India Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
7.4.6.10. Australia Market Size and Forecast for Ulcerative Colitis Market by Disease Type
7.4.6.11. Australia Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
7.4.6.12. Australia Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
7.4.6.13. South Korea Market Size and Forecast for Ulcerative Colitis Market by Disease Type
7.4.6.14. South Korea Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
7.4.6.15. South Korea Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
7.4.6.16. Rest of Asia-Pacific Market Size and Forecast for Ulcerative Colitis Market by Disease Type
7.4.6.17. Rest of Asia-Pacific Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
7.4.6.18. Rest of Asia-Pacific Market Size and Forecast for Ulcerative Colitis Market by Route of Administration

7.5. LAMEA

7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. LAMEA Market Size and Forecast for Ulcerative Colitis Market by Country
7.5.4. LAMEA Market Size and Forecast for Ulcerative Colitis Market by Disease Type
7.5.5. LAMEA Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
7.5.6. LAMEA Market Size and Forecast for Ulcerative Colitis Market by Route of Administration

7.5.6.1. South Africa Market Size and Forecast for Ulcerative Colitis Market by Disease Type
7.5.6.2. South Africa Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
7.5.6.3. South Africa Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
7.5.6.4. Saudi Arabia Market Size and Forecast for Ulcerative Colitis Market by Disease Type
7.5.6.5. Saudi Arabia Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
7.5.6.6. Saudi Arabia Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
7.5.6.7. Israel Market Size and Forecast for Ulcerative Colitis Market by Disease Type
7.5.6.8. Israel Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
7.5.6.9. Israel Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
7.5.6.10. Rest of LAMEA Market Size and Forecast for Ulcerative Colitis Market by Disease Type
7.5.6.11. Rest of LAMEA Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
7.5.6.12. Rest of LAMEA Market Size and Forecast for Ulcerative Colitis Market by Route of Administration

CHAPTER 8 COMPANY PROFILES

8.1. PFIZER INC.

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Business performance
8.1.5. Key strategic moves and developments

8.2. JOHNSON & JOHNSON

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Business performance
8.2.5. Key strategic moves and developments

8.3. GLAXOSMITHKLINE PLC

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Business performance
8.3.5. Key strategic moves and developments

8.4. ELI LILLY AND CO.

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Business performance
8.4.5. Key strategic moves and developments

8.5. SANOFI AVENTIS A/S

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Business performance
8.5.5. Key strategic moves and developments

8.6. ASTRAZENECA PLC

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Business performance
8.6.5. Key strategic moves and developments

8.7. MERCK & CO. INC.

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Business performance
8.7.5. Key strategic moves and developments

8.8. ABBOTT LABORATORIES

8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Business performance
8.8.5. Key strategic moves and developments

8.9. INDEX PHARMACEUTICALS HOLDING AB

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Key strategic moves and developments

8.10. AJINOMOTO PHARMACEUTICALS CO., LTD.

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Key strategic moves and developments